Impact of extremely low-frequency electromagnetic field (100 Hz, 100 G) exposure on human glioblastoma U87 cells during Temozolomide administration.

PAPER pubmed Electromagnetic biology and medicine 2019 In vitro study Effect: mixed Evidence: Very low

Read original paper → DOI: 10.1080/15368378.2019.1625784 PMID: 31179753 Evidence Lab

Abstract

Glioblastoma multiforme (GBM) is a highly malignant brain tumor with an extremely dismal prognosis, a median survival is12 months. Temozolomide (TMZ) is an alkylating agent widely used to treat cancer, resistance to this drug is often found. One unexplored possibility for overcoming this resistance is a treatment based on concomitant exposure to electromagnetic fields (EMF) and TMZ. Indeed, many evidences show that EMF affects cancer cells and drug performance. Therefore, the present study was carried out to evaluate the potential synergistic effect of 100 µM TMZ and EMF (100 Hz, 100 G) on human glioma cell line U87 U87 cells with four experimental groups (I-IV) were exposed to ELF-EMF and TMZ for 120 and 144 h, as follows: (I) control; (II) ELF-EMF; (III) TMZ; (IV) ELF-PEMFs / TMZ. mRNA expression of genes such as (Nestin,CD133, Notch4 and GFAP) were investigated by Real-time PCR and western blot. We also evaluated, SOD activity, MDA and calcium concentration by ELISA assay. Co-treatment synergistically decreased the expression of Nestin,CD133, and Notch4 and increased the GFAP genes. We also observed an increase in Superoxide dismutase (SOD) activity, Malondialdehyde (MDA) and Ca2+concentration in comparison to controls.TMZ prevents cancer progression not only through the induction of cell death, but also by inducing differentiation in cancer cells. In addition, our data demonstrate ELF-EMF (100 Hz, 100 G) can significantly enhance the effects of TMZ on human glioblastoma U87 cell. These findings may open new window for future studies.

AI evidence extraction

At a glance

Study type

In vitro study

Effect direction

mixed

Population

Human glioblastoma U87 cell line (U87 cells)

Sample size

—

Exposure

ELF · 0.0001 MHz · 120 and 144 h

Evidence strength

Very low

Confidence: 78% · Peer-reviewed: yes

Main findings

Co-treatment with temozolomide (100 µM) and ELF-EMF (100 Hz, 100 G) decreased Nestin, CD133, and Notch4 expression and increased GFAP expression compared with controls. Co-treatment was also associated with increased SOD activity, MDA, and Ca2+ concentration versus controls, and the authors report ELF-EMF significantly enhanced TMZ effects in U87 cells.

Outcomes measured

mRNA/protein expression of Nestin
mRNA/protein expression of CD133
mRNA/protein expression of Notch4
mRNA/protein expression of GFAP
Superoxide dismutase (SOD) activity
Malondialdehyde (MDA) level
Calcium (Ca2+) concentration

Limitations

In vitro study in a single human glioblastoma cell line (U87)
Sample size not reported in abstract
Exposure metric reported as 100 G magnetic field; dosimetry/SAR not provided
Outcomes are molecular/biochemical markers; clinical relevance not assessed

View raw extracted JSON

{
    "study_type": "in_vitro",
    "exposure": {
        "band": "ELF",
        "source": null,
        "frequency_mhz": 0.000100000000000000004792173602385929598312941379845142364501953125,
        "sar_wkg": null,
        "duration": "120 and 144 h"
    },
    "population": "Human glioblastoma U87 cell line (U87 cells)",
    "sample_size": null,
    "outcomes": [
        "mRNA/protein expression of Nestin",
        "mRNA/protein expression of CD133",
        "mRNA/protein expression of Notch4",
        "mRNA/protein expression of GFAP",
        "Superoxide dismutase (SOD) activity",
        "Malondialdehyde (MDA) level",
        "Calcium (Ca2+) concentration"
    ],
    "main_findings": "Co-treatment with temozolomide (100 µM) and ELF-EMF (100 Hz, 100 G) decreased Nestin, CD133, and Notch4 expression and increased GFAP expression compared with controls. Co-treatment was also associated with increased SOD activity, MDA, and Ca2+ concentration versus controls, and the authors report ELF-EMF significantly enhanced TMZ effects in U87 cells.",
    "effect_direction": "mixed",
    "limitations": [
        "In vitro study in a single human glioblastoma cell line (U87)",
        "Sample size not reported in abstract",
        "Exposure metric reported as 100 G magnetic field; dosimetry/SAR not provided",
        "Outcomes are molecular/biochemical markers; clinical relevance not assessed"
    ],
    "evidence_strength": "very_low",
    "confidence": 0.7800000000000000266453525910037569701671600341796875,
    "peer_reviewed_likely": "yes",
    "keywords": [
        "extremely low-frequency",
        "ELF-EMF",
        "100 Hz",
        "100 G",
        "pulsed electromagnetic fields",
        "PEMF",
        "temozolomide",
        "TMZ",
        "glioblastoma",
        "U87",
        "Nestin",
        "CD133",
        "Notch4",
        "GFAP",
        "SOD",
        "MDA",
        "calcium"
    ],
    "suggested_hubs": []
}

AI can be wrong. Always verify against the paper.

AI-extracted fields are generated from the abstract/metadata and may be incomplete or incorrect. This content is for informational purposes only and is not medical advice.

Comments

No comments yet.